Exenatide Versus Glimepiride in Patients With Type 2 Diabetes

NCT00359762 · Completed

Last updated 2026-05-28

This clinical trial compared the effects of exenatide and glimepiride in adults with type 2 diabetes to see which medication was more effective at preventing treatment failure.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 1,029 people

Who can join Ages 18–85 · all sexes

Timeline Started 2006-09 · est. completion 2011-03

Where 114 sites · Austria, Czechia, Finland, France, Germany, Hungary, Ireland, Israel, Italy, Mexico, Poland, Spain, Switzerland, United Kingdom

What this study is testing ClinicalTrials.gov NCT00359762 ↗

Description as written by the study sponsor.

This study assesses the effects of twice-daily subcutaneous injection exenatide versus treatment with sulfonylurea (glimepiride) on long-term glycemic control and beta-cell function.

Treatments tested

exenatide also known as Byetta Drug

subcutaneous injection (5mcg or 10mcg), twice a day
glimepiride also known as Amaryl Drug

oral tablet (titrated to maximally tolerated dose), once daily

Main thing measured	Number of Patients With Treatment Failure
Sponsor	AstraZeneca
Conditions studied	Type 2 Diabetes Mellitus
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00359762 ↗